Alte oder neue Antihypertensiva?

Literatur

• 1 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting-enzyme inhibitor or calcium channel blocker vs diuretic.  JAMA. 2002;  288 2981-2997
• 2 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . Major cardiovascular events in hypertensiven patients randomised to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).  JAMA. 2000;  283 1967-1975
• 3 Davis B R, Cutler J A, Furberg C D. et al . Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).  Ann Intern Med. 2002;  137 313-320
• 4 Appel L J. The verdict from ALLHAT - thiazide diuretics are the preferred initial therapy for hypertension.  JAMA. 2002;  288 3039-3042
• 5 WHO-ISH Hypertension Guidelines Committee, 1999 World Health Organization . International Society of Hypertension Guidelines for the Management of Hypertension.  J Hypertens. 1999;  17 151-183
• 6 Sever P S, Dahlöf B. et al . Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian cardiac outcomes trial. ASCOT investigators.  J Hypertens. 2001;  19 1139-1147
• 7 Hansson L, Lindholm L H, Niskanen L. et al. for the Captopril Primary Prevention Project (CAPPP) study group . Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Primary Prevention Project (CAPPP).  Lancet. 1999;  353 611-616
• 8 Hansson L, Lindholm L H, Ekbom T. et al. for the STOP-Hypertension-2 study group . Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.  Lancet. 1999;  354 1751-1756
• 9 Dahlöf B, Devereux R B, Kjeldsen S E. et al. The LIFE Study Group . Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.  Lancet. 2002;  359 995-1003
• 10 Lindholm L H, Ibsen H, Dahlöf B. et al. The LIFE Study Group . Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction study (LIFE): a randomised trial against atenolol.  Lancet. 2002;  359 1004-1010
• 11 Kjeldsen S E, Dahlöf B, Devereux R B. et al. LIFE Study Group . Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a losartan intervention for endpoint reduction (LIFE) substudy.  JAMA. 2002;  288 1491-1498
• 12 Mann J, Julius S. The valsartan antihypertensive long-term use evaluation (VALUE) trial of cardiovascular events in hypertension: Rationale and design.  Blood Press. 1998;  7 176-183